AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 232 min read$BCPC

Quarterly sales and profit set records at Balchem. Sales reached $290.7 million.

Balchem (NASDAQ: BCPC) reported record Q3 2026 sales of $290.7M, up 8.6% YoY, with net earnings of $46.7M, up 16.0%. Adjusted EBITDA was $80.3M, up 12.4%. All segments showed growth. The company repurchased $28M in stock during the quarter.

Original reporting
stocktitan.net
Published Oct 23, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 11:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BCPC
Bullish
high confidence
Mentioned
$BCPC
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$BCPCBullishHigh
01

Why it matters

Record sales and earnings may drive short-term price appreciation.

02

Market read

First report of Balchem's quarterly results, providing fresh data for traders.

03

What to watch

Potential headwinds from raw material costs not discussed.

Relevance 7/10Novelty 8/10Timing: today

Background

Balchem's Q3 2026 earnings release via GlobeNewswire.

Company-level read

Ticker impact

$BCPCBullishHigh confidence
Context

Balchem reported Q3 2026 net sales of $290.7M (+8.6% YoY) and GAAP EPS of $1.46, setting quarterly records.

Expected impact

likely upward pressure as market prices in record earnings

Evidence & confidence

Strong top-line growth and earnings beat suggest investors will bid the stock higher.

Market effects

Sector

Boosts confidence in nutrition and health ingredient sector.

Regional

Positive for US specialty chemicals market.

Global

Limited to specialty chemicals niche.

Counterpoint

What could challenge this read

If guidance is modest, the stock may already be priced in.

Key entities

  • company
    Balchem Corporation

    US-listed specialty chemicals firm (NASDAQ: BCPC).

Read at source← All news

StoryBalchem posts record Q3 2026 sales and earnings, repurchases $28 million of stock

Also covered by

2 outlets

Related articles

OCT 23
$BCPCHigh

Balchem beats Q3 estimates on strong segment growth

Balchem Corporation (NASDAQ:BCPC) reported Q3 adjusted EPS of $1.57, beating estimates of $1.43. Revenue was $290.7M, up 8.6% YoY. All segments showed growth, with Human Nutrition sales at $188.2M, Animal Nutrition at $63.0M, and Specialty Products at $37.3M. Gross margin improved to 36.4%. The company repurchased $28M in stock during the quarter.

investing.com2 min
OCT 23
$BCPCMed

Balchem Corporation Reports Third Quarter 2026 Financial Results

BALCHEM CORP (BCPC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Human Nutrition & Health | Animal Nutrition & Health | Specialty Products Balchem Corporation Reports Third Quarter 2026 Financial Results Montvale, NJ, October 23, 2026 - Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal third q

SEC EDGAR 8-K2 min
JUL 31
$BCPCMed

Balchem Corporation Reports Second Quarter 2026 Financial Results

BALCHEM CORP (BCPC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Human Nutrition & Health | Animal Nutrition & Health | Specialty Products Balchem Corporation Reports Second Quarter 2026 Financial Results Montvale, NJ, July 31, 2026 - Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal second qu

SEC EDGAR 8-K6 min